Daniel Eduardo Gómez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6524938/publications.pdf

Version: 2024-02-01

90 papers 3,178 citations

147786 31 h-index 53 g-index

91 all docs 91 docs citations

times ranked

91

3619 citing authors

#	Article	IF	CITATIONS
1	Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology, 2000, 32, 1248-1254.	7.3	233
2	Ras oncogene mediated induction of a 92kDa metalloproteinase; strong correlation with the malignant phenotype. Biochemical and Biophysical Research Communications, 1988, 154, 832-838.	2.1	202
3	Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. FEBS Journal, 1999, 263, 295-304.	0.2	170
4	The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. International Journal of Cancer, 2001, 94, 768-773.	5.1	145
5	Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Research and Treatment, 1998, 50, 83-93.	2.5	135
6	Telomere structure and telomerase in health and disease. International Journal of Oncology, 2012, 41, 1561-1569.	3.3	126
7	Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1show vascular endothelial growth factor expression. International Journal of Cancer, 1998, 75, 81-87.	5.1	111
8	CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both inAvitro and inAvivo. Molecular and Cellular Biochemistry, 2008, 316, 163-167.	3.1	86
9	Irreversible Telomere Shortening by 3′-Azido-2′, 3′-Dideoxythymidine (AZT) Treatment. Biochemical and Biophysical Research Communications, 1998, 246, 107-110.	2.1	80
10	NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines. Clinical and Developmental Immunology, 2010, 2010, 1-8.	3.3	67
11	Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 840-851.	1.7	67
12	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. International Journal of Cancer, 2008, 122, 57-62.	5.1	64
13	Tumor invasion, proteolysis, and angiogenesis. Journal of Neuro-Oncology, 1994, 18, 89-103.	2.9	63
14	Telomerase as a Cancer Target. Development of New Molecules. Current Topics in Medicinal Chemistry, 2016, 16, 2432-2440.	2.1	62
15	Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clinical and Experimental Metastasis, 2002, 19, 551-560.	3.3	58
16	Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. , 1996, 69, 131-134.		52
17	The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipooxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target. PLoS ONE, 2012, 7, e40794.	2.5	51
18	New drugs are not enoughâ€'drug repositioning in oncology: An update. International Journal of Oncology, 2020, 56, 651-684.	3.3	50

#	Article	IF	Citations
19	Neurogenic differentiation of human adipose-derived stem cells: Relevance of different signaling molecules, transcription factors, and key marker genes. Gene, 2012, 511, 427-436.	2.2	49
20	AZT as a telomerase inhibitor. Frontiers in Oncology, 2012, 2, 113.	2.8	45
21	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Molecular and Cellular Biochemistry, 2011, 356, 45-50.	3.1	41
22	Partial Characterization of Novel Serine Proteinase Inhibitors from Human Umbilical Vein Endothelial Cells. Archives of Biochemistry and Biophysics, 1995, 319, 55-62.	3.0	40
23	The role of protein kinase C and novel phorbol ester receptors in tumor cell invasion and metastasis (Review) Oncology Reports, 1999, 6, 1363-70.	2.6	40
24	Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine. Journal of Immunotherapy, 2004, 27, 442-451.	2.4	39
25	Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin. Current Pharmaceutical Biotechnology, 2011, 12, 1974-1980.	1.6	39
26	Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides Oncology Reports, 2000, 7, 751-6.	2.6	37
27	Chronic In Vitro Exposure to 3′-Azido-2′, 3′-Dideoxythymidine Induces Senescence and Apoptosis and Reduces Tumorigenicity of Metastatic Mouse Mammary Tumor Cells. Breast Cancer Research and Treatment, 2001, 65, 93-99.	2.5	36
28	Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. Journal of Surgical Oncology, 2002, 81, 38-44.	1.7	36
29	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Research and Treatment, 2013, 142, 9-18.	2.5	34
30	A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. SpringerPlus, 2015, 4, 428.	1.2	34
31	Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Research and Treatment, 1999, 57, 271-275.	2.5	32
32	Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Veterinary Journal, 2008, 178, 103-108.	1.7	32
33	Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and its Relation to Histologic Grade. Journal of the American Animal Hospital Association, 2011, 47, 21-27.	1.1	32
34	Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cellular Signalling, 2017, 30, 154-161.	3.6	32
35	New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis. Cellular and Molecular Life Sciences, 2021, 78, 2893-2910.	5.4	31
36	Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Review of Vaccines, 2003, 2, 817-823.	4.4	30

#	Article	IF	Citations
37	Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. Frontiers in Oncology, 2012, 2, 150.	2.8	30
38	Antiproliferative effect of 1-deamino-8- <scp>D</scp> -arginine vasopressin analogs on human breast cancer cells. Future Medicinal Chemistry, 2011, 3, 1987-1993.	2.3	28
39	Sensitivity of tumor cells towards CIGBâ€300 anticancer peptide relies on its nucleolar localization. Journal of Peptide Science, 2012, 18, 215-223.	1.4	28
40	The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. International Journal of Oncology, 2015, 46, 2335-2345.	3.3	28
41	A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Research, 2001, 11, 219-227.	1.2	27
42	Transcriptional Characterization of Wnt and Notch Signaling Pathways in Neuronal Differentiation of Human Adipose Tissue-Derived Stem Cells. Journal of Molecular Neuroscience, 2011, 44, 186-194.	2.3	27
43	Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. OncoTargets and Therapy, 2014, 7, 2021.	2.0	26
44	Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model. Clinical Cancer Research, 2006, 12, 7092-7098.	7.0	21
45	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. Experimental Cell Research, 2011, 317, 1677-1688.	2.6	20
46	Expression of gelatinise/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clinical and Experimental Metastasis, 1992, 10, 211-220.	3.3	19
47	Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. Journal of Experimental and Clinical Cancer Research, 2009, 28, 146.	8.6	18
48	Differential Expression of Shh and BMP Signaling in the Potential Conversion of Human Adipose Tissue Stem Cells Into Neuron-Like Cells In Vitro. Gene Expression, 2010, 14, 307-319.	1.2	18
49	Telomerase regulation: A key to inhibition?. International Journal of Oncology, 2013, 43, 1351-1356.	3.3	18
50	Protein universe containing a <scp>PUA RNA</scp> â€binding domain. FEBS Journal, 2014, 281, 74-87.	4.7	18
51	Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines. Molecular Pharmaceutics, 2014, 11, 1798-1807.	4.6	18
52	Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis, 2004, 25, 1735-1746.	2.8	17
53	Telomeropathies: Etiology, diagnosis, treatment and followâ€up. Ethical and legal considerations. Clinical Genetics, 2019, 96, 3-16.	2.0	17
54	Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in Oncology, 2012, 2, 160.	2.8	16

#	Article	IF	CITATIONS
55	Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Research, 2008, 28, 2607-11.	1.1	16
56	Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. Anticancer Research, 2010, 30, 5049-54.	1.1	16
57	Immunomagnetic separation as a final purification step of liver endothelial cells. In Vitro Cellular & Developmental Biology, 1993, 29, 451-455.	1.0	15
58	Homology Model and Docking-Based Virtual Screening for Ligands of Human Dyskerin as New Inhibitors of Telomerase for Cancer Treatment. International Journal of Molecular Sciences, 2018, 19, 3216.	4.1	15
59	Preclinical Efficacy of [V4 Q5]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer. Cancer Research and Treatment, 2019, 51, 438-450.	3.0	15
60	RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging. Cell Death and Disease, 2015, 6, e1902-e1902.	6.3	14
61	Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In Vivo, 2012, 26, 609-17.	1.3	14
62	Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Molecular Medicine Reports, 2014, 9, 2568-2572.	2.4	13
63	AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model. Oncology Reports, 2016, 36, 2731-2736.	2.6	13
64	Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Research, 2014, 34, 4761-5.	1.1	13
65	Ulex Europaeus I Lectin Induces Activation of Matrix-Metalloproteinase-2 in Endothelial Cells. Biochemical and Biophysical Research Communications, 1995, 216, 177-182.	2.1	12
66	Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clinical and Experimental Metastasis, 2016, 33, 589-600.	3.3	12
67	Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: Enhancement by paclitaxel and inhibition by nocodazole., 1999, 83, 242-246.		11
68	Liver tumors and possible preneoplastic lesions, induced by a foodâ€derived heterocyclic amine in cynomolgus monkeys; a study of histology and cytokeratin expression. Liver, 1996, 16, 71-83.	0.1	11
69	Expression and Characterization of Human Tissue Inhibitor of Metalloproteinases-1 in a Baculovirus-Insect Cell System. Biochemical and Biophysical Research Communications, 1994, 203, 237-243.	2.1	10
70	Role of Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor in MiceBear ing a Highly Invasive and Metastatic Mammary Carcinoma. Pathobiology, 1999, 67, 180-185.	3.8	10
71	Cancer Antigen Prioritization: A Road Map to Work in Defining Vaccines Against Specific Targets. A Point of View. Frontiers in Oncology, 2012, 2, 66.	2.8	9
72	Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium., 1996, 60, 148-160.		8

#	Article	IF	Citations
73	Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model. Journal of Cancer Research and Clinical Oncology, 2002, 128, 669-677.	2.5	8
74	Histopathological findings in a highly invasive mouse mammary carcinoma transfected with human tissue inhibitor of metalloproteinases-1 Oncology Reports, 1998, 5, 1083-7.	2.6	8
75	Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing Î ² 2-chimaerin. Molecular Medicine Reports, 2008, 2, 97-102.	2.4	7
76	Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity. Frontiers in Cell and Developmental Biology, 2020, 8, 240.	3.7	7
77	Effect of Host-Organ Environment on the in vivo and in vitro Behavior of a Murine Mammary Adenocarcinoma. Tumor Biology, 1994, 15, 284-293.	1.8	6
78	Tissue factor as a novel marker for detection of circulating cancer cells. Biomarkers, 2011, 16, 58-64.	1.9	6
79	In Vitro Activity of a Solanum tuberosum Extract against Mammary Carcinoma Cells. Planta Medica, 2001, 67, 164-166.	1.3	5
80	Novel Insights into the Evolution and Structural Characterization of Dyskerin Using Comprehensive Bioinformatics Analysis. Journal of Proteome Research, 2015, 14, 874-887.	3.7	5
81	Dietary factors, genetic and epigenetic influences in colorectal cancer. Experimental and Therapeutic Medicine, 2010, 1, 241-250.	1.8	4
82	In vivo selection and characterization of a murine mammary tumor subline with high potential for spontaneous lymph node metastasis. Journal of Surgical Oncology, 1990, 45, 190-195.	1.7	3
83	Contractile Behaviour of Rat Seminal Vesicle after Gonadectomy, Testosterone Replacement and Cyproterone Treatment. Andrologia, 1985, 17, 435-439.	2.1	3
84	Mammary carcinoma cells overâ€expressing tissue inhibitor of metalloproteinasesâ€1show vascular endothelial growth factor expression. International Journal of Cancer, 1998, 75, 81-87.	5.1	3
85	Lectins as Tools for the Purification of Liver Endothelial Cells. , 1998, 9, 319-328.		2
86	Anti-idiotype antibodies in cancer treatment. Frontiers in Oncology, 2013, 3, 37.	2.8	2
87	Inhibition of fibrinolysis by a synthetic urokinase inhibitor enhances lung colonization of metastatic murine mammary tumor cells. Oncology Reports, 1996, 3, 1055-8.	2.6	2
88	Thrombin treatment of endothelial cells stimulates adhesion of oncogene transformed but not parent rat liver epithelial cells. Thrombosis Research, 1995, 78, 87-94.	1.7	1
89	Enhanced RNA expression of tissue inhibitor of metalloproteinasesâ€1 (TIMPâ€1) in human breast cancer. International Journal of Cancer, 1996, 69, 131-134.	5.1	1
90	Effect of atorvastatin in a case of feline multicentric lymphoma â€" Case report. Acta Veterinaria Hungarica, 2011, 59, 69-76.	0.5	0